Alzheimer's disease

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

Retrieved on: 
Wednesday, December 14, 2022

Prof. Dr. Grimmer served as National Coordinating Investigator for the ANAVEX®2-73 (blarcamesine) Phase 2b/3 ANAVEX®2-73-AD-004 study.

Key Points: 
  • Prof. Dr. Grimmer served as National Coordinating Investigator for the ANAVEX®2-73 (blarcamesine) Phase 2b/3 ANAVEX®2-73-AD-004 study.
  • The main focus of Prof. Dr. Grimmer’s research is assessing the usefulness of biomarkers in predicting neurocognitive disorders.
  • In addition, he has served as a national coordinating investigator and as a principal investigator in more than 70 drug trials including all monoclonal antibodies against cerebral amyloid load.
  • “I’m excited to join Anavex’s Scientific Advisory Board at this time of important growth and evolution of the Company,” said Professor Dr. Grimmer.

Citrine Global Corp. (CTGL) Signs MOU with MyPlant Bio, Specialized in Botanical Drug Development, to Acquire 55% of MyPlant’s Shares against Citrine Global Shares

Retrieved on: 
Tuesday, December 13, 2022

Under the terms of the MOU, Citrine Global will have the option to acquire 55% of MyPlant’s shares for a purchase price of USD 2.44 million, payable with Citrine Global shares at the Citrine Global valuation of USD 45 Million, which was Citrine Global’s valuation on the day of the execution of the MOU.

Key Points: 
  • Under the terms of the MOU, Citrine Global will have the option to acquire 55% of MyPlant’s shares for a purchase price of USD 2.44 million, payable with Citrine Global shares at the Citrine Global valuation of USD 45 Million, which was Citrine Global’s valuation on the day of the execution of the MOU.
  • The acquisition is subject to Citrine Global’s sole decision and the execution of the Definitive Agreement and due diligence.
  • Citrine Global’s acquisition of MyPlant is in line with the Citrine Global’s strategy to be a leader in plant-based wellness and pharma solutions.
  • [online] GlobeNewswire News Room
    2 Inkwood Research, Botanical and Plant Derivative Drug Market - Global Forecast 2018-2026.

Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, December 12, 2022

Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 08:15 AM - 08:55 AM (Pacific Time).

Key Points: 
  • Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 08:15 AM - 08:55 AM (Pacific Time).
  • A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com .
  • About Anavex Life Sciences Corp.
    Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer.
  • All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy

Retrieved on: 
Wednesday, December 7, 2022

Tel-Aviv, Dec. 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced positive results from its study of SCI-210 on Status Epilepticus ("SE"), conducted at The Sheba Fund for Health Services and Research at Chaim Sheba Medical Center, which reaffirm the potential of its proprietary combination products to have a positive effect while minimizing adverse side effects. The Company's proprietary SCI-210 platform combines Palmitoylethanolamide (“PEA”) with Cannabidiol (“CBD”).

Key Points: 
  • The non-clinical trial objective was to study the potential therapeutic effects of SCI-210 on SE and on neuro-biochemical markers for neurological cognitive sequelae.
  • A pilocarpine SE-induced mice (C57BL/6 male) model to study SCI-210’s effects on seizure severity and mortality was used.
  • The results indicated differences in mortality rate as well as seizure rates over time.
  • There is limited pharmaceutical treatment available for treating epilepsy, as about one in three patients have drug- resistance against epilepsy," said Adi Zuloff-Shani, PhD, Chief Technology Officer of SciSparc.

Todos Medical to Present at the RHK 2022 Disruptive Growth Conference

Retrieved on: 
Tuesday, December 6, 2022

New York, NY, and Tel Aviv, ISRAEL, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its President & CEO Gerald Commissiong will be presenting at the RHK 2022 Disruptive Growth Conference on Tuesday, December 6th at 12:20pm ET.

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its President & CEO Gerald Commissiong will be presenting at the RHK 2022 Disruptive Growth Conference on Tuesday, December 6th at 12:20pm ET.
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Sunrise Senior Living Reopens Sunrise of Redmond

Retrieved on: 
Thursday, December 15, 2022

Today, Sunrise Senior Living, an industry pioneer and leading provider of senior living services, announced the reopening of Sunrise of Redmond in Bellevue, Washington after an extensive renovation of the community.

Key Points: 
  • Today, Sunrise Senior Living, an industry pioneer and leading provider of senior living services, announced the reopening of Sunrise of Redmond in Bellevue, Washington after an extensive renovation of the community.
  • (Photo: Business Wire)
    Sunrises personalized approach has become a gold standard for the senior living industry throughout its 40-year history.
  • We are thrilled to welcome residents to the new and improved Sunrise of Redmond, said Sunrise of Redmonds Executive Director, Ashley Hineline.
  • Founded in 1981, Sunrise Senior Living is credited with establishing the modern era of senior living.

Global Drug Delivery Across Blood-Brain Barrier Market Report 2022 to 2027: Players Include 3M, AbbVie, Bioasis Technologies, ICON and Pfizer - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 13, 2022

The "Global Drug Delivery across Blood-Brain Barrier Market (2022-2027) by Drug Delivery Technology, Application, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Drug Delivery across Blood-Brain Barrier Market (2022-2027) by Drug Delivery Technology, Application, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The report presents a detailed Ansoff matrix analysis for the Global Drug Delivery across Blood-Brain Barrier Market.
  • The report offers a comprehensive evaluation of the Global Drug Delivery across Blood-Brain Barrier Market.
  • Growing Incidences of Neurological Disorders, Such as Alzheimer's Disease
    The Global Drug Delivery across Blood-Brain Barrier Market is segmented based on Drug Delivery Technology, Application, and Geography.

Global Glycomic Therapeutics Market Forecast to 2028 - Wide Applications of Glycomics in Therapeutics Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 13, 2022

The "Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class, Structures, Indications, and Mode of Action" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class, Structures, Indications, and Mode of Action" report has been added to ResearchAndMarkets.com's offering.
  • The global glycomic therapeutics market is expected to grow from US$ 99,021.46 million in 2021 to US$ 257,578.79 million in 2028; it is estimated to grow with a CAGR of 15.8% from 2022 to 2028.
  • Glycan-based therapeutics have wide applications in the pharmaceutical industry; the products are available in different structures & forms and developed as per the application.
  • The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells.

Insightec Announces Milestone of First Patients Enrolled in the Pivotal LIBERATE Clinical Trial (Liquid Biopsy with Low Intensity Ultrasound in Brain Tumors)

Retrieved on: 
Thursday, December 15, 2022

HAIFA, Israel & MIAMI, Dec. 15, 2022 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, announced today the first patients have enrolled in the pivotal LIBERATE clinical trial (Liquid Biopsy with Low Intensity Ultrasound in Brain Tumors). Enrollment in LIBERATE marks the start of an international effort to assess safety and efficacy of using Insightec's focused ultrasound (FUS) platform to temporarily disrupt the blood brain barrier (BBB) to enable liquid biopsies in patients with glioblastoma, the most common primary malignant brain tumor in adults.

Key Points: 
  • HAIFA, Israel & MIAMI, Dec. 15, 2022 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, announced today the first patients have enrolled in the pivotal LIBERATE clinical trial (Liquid Biopsy with Low Intensity Ultrasound in Brain Tumors).
  • "Our team at Mayo Clinic is excited to have enrolled the first patient in this pivotal trial," said neurosurgeon Terry Burns MD PhD.
  • Importantly, FUS can be repeated non-invasively, allowing a rare molecular window into individual patient's brain tumors as they evolve during treatment."
  • "Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether standing alone or in connection with the word "Insightec", are protected trademarks of Insightec.